Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
372 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02947165 | Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. | completed | Phase 1 | 120 | Novartis PharmaceuticalsINDUSTRY | 9 | Jan 31, 2022 | clinicaltrials |
| NCT03084926 | First-in-human Study to Investigate Safety, Blood Levels and Activity of MP0274 in Cancer Patients With HER2-positive Solid Tumors | completed | Phase 1 | 22 | Molecular Partners AGINDUSTRY | 3 | Jan 10, 2022 | clinicaltrials |
| NCT05136521 | Bioavailability Study of 300 mg Trazodone Hydrochloride (New Polymer) vs. 300 mg Trazodone Hydrochloride (Contramid® Prolonged-release Tablets) Under Fasting Conditions | completed | Phase 1 | 28 | Aziende Chimiche Riunite Angelini Francesco S.p.AINDUSTRY | 1 | Nov 29, 2021 | clinicaltrials |
| NCT01644994 | Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma | completed | Phase 1 / Phase 2 | 47 | University of ZurichOTHER | 1 | Sep 29, 2021 | clinicaltrials |
| NCT02145130 | Phase I Study for Autologous Dermal Substitutes and Dermo-epidermal Skin Substitutes for Treatment of Skin Defects | completed | Phase 1 | 12 | University of ZurichOTHER | 1 | Sep 8, 2021 | clinicaltrials |
| NCT02626000 | Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137)(MASTERKEY232) | completed | Phase 1 | 36 | AmgenINDUSTRY | 11 | Sep 8, 2021 | clinicaltrials |
| NCT00040599 | Safety Study of 90Y-hMN14 to Treat Colorectal Cancer | completed | Phase 1 / Phase 2 | 72 | Gilead SciencesINDUSTRY | 5 | Aug 19, 2021 | clinicaltrials |
| NCT02807844 | Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 141 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 11, 2021 | clinicaltrials |
| NCT03098550 | A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread | completed | Phase 1 / Phase 2 | 105 | Bristol-Myers SquibbINDUSTRY | 9 | Jul 23, 2021 | clinicaltrials |
| NCT02964689 | Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC. | completed | Phase 1 | 18 | Swiss Cancer InstituteOTHER | 1 | Jul 14, 2021 | clinicaltrials |
| NCT00109707 | A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies | completed | Phase 1 / Phase 2 | 507 | Novartis PharmaceuticalsINDUSTRY | 22 | Jun 29, 2021 | clinicaltrials |
| NCT03687125 | Tinostamustine Conditioning and Autologous Stem Cell(TITANIUM1) | terminated | Phase 1 / Phase 2 | 6 | Mundipharma-EDO GmbHINDUSTRY | 3 | Jun 18, 2021 | clinicaltrials |
| NCT01760525 | A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors(CCGM097X2101) | completed | Phase 1 | 51 | Novartis PharmaceuticalsINDUSTRY | 5 | Jun 15, 2021 | clinicaltrials |
| NCT01222637 | CetuGEX™: Phase 1 Study in Cancer Patients | completed | Phase 1 | 41 | Glycotope GmbHINDUSTRY | 3 | May 25, 2021 | clinicaltrials |
| NCT01222624 | PankoMab-GEX™: Phase 1 Dose Escalation Study | completed | Phase 1 | 74 | Glycotope GmbHINDUSTRY | 3 | May 20, 2021 | clinicaltrials |
| NCT01409343 | TrasGEX™: Phase 1 Study in Cancer Patients | completed | Phase 1 | 37 | Glycotope GmbHINDUSTRY | 4 | May 7, 2021 | clinicaltrials |
| NCT01976741 | Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib) | completed | Phase 1 | 168 | BayerINDUSTRY | 7 | May 6, 2021 | clinicaltrials |
| NCT03421236 | Intravesical Ty21a for the Treatment of Patients With Non-muscle-invasive Bladder Cancer (NMIBC) | unknown | Phase 1 | 25 | Patrice JichlinskiOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT02903069 | Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer | completed | Phase 1 | 66 | CelgeneINDUSTRY | 3 | Apr 19, 2021 | clinicaltrials |
| NCT04839120 | PK, PD, Tolerability and Safety of MDPK67b in Healthy Volunteers | completed | Phase 1 | 8 | Med Discovery SAINDUSTRY | 1 | Apr 9, 2021 | clinicaltrials |
| NCT03992326 | Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors | terminated | Phase 1 | 6 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Mar 18, 2021 | clinicaltrials |
| NCT01700270 | Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors.(CTKI258A2120) | completed | Phase 1 | 45 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 21, 2020 | clinicaltrials |
| NCT00304525 | A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma(CHIR-265-MEL01) | completed | Phase 1 / Phase 2 | 104 | Novartis PharmaceuticalsINDUSTRY | 2 | Dec 19, 2020 | clinicaltrials |
| NCT00570284 | A Study to Investigate the Effect of Food on Oral LBH589 Absorption in Patients With Advanced Solid Tumors | completed | Phase 1 | 36 | Novartis PharmaceuticalsINDUSTRY | 3 | Dec 19, 2020 | clinicaltrials |
| NCT00880308 | Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors | completed | Phase 1 | 103 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 19, 2020 | clinicaltrials |
| NCT00997399 | Study to Evaluate Panobinostat (DACi) Pharmacokinetics and Safety in Solid Tumors and Varying Renal Function | completed | Phase 1 | 37 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 19, 2020 | clinicaltrials |
| NCT01007968 | Pharmacokinetics and Safety of Panobinostat in Patients With Advanced Solid Tumors and Various Degrees of Hepatic Function | completed | Phase 1 | 25 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 19, 2020 | clinicaltrials |
| NCT00526045 | Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients | completed | Phase 1 / Phase 2 | 117 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 17, 2020 | clinicaltrials |
| NCT01106508 | A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors | completed | Phase 1 | 57 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 17, 2020 | clinicaltrials |
| NCT01830010 | A Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies | completed | Phase 1 | 23 | Novartis PharmaceuticalsINDUSTRY | 3 | Dec 11, 2020 | clinicaltrials |
| NCT01155453 | A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients | completed | Phase 1 | 113 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 9, 2020 | clinicaltrials |
| NCT01285466 | A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab | completed | Phase 1 | 110 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 9, 2020 | clinicaltrials |
| NCT01613950 | PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer | completed | Phase 1 | 18 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 9, 2020 | clinicaltrials |
| NCT01928459 | Phase 1b Trial of BGJ398/BYL719 in Solid Tumors | completed | Phase 1 | 62 | Novartis PharmaceuticalsINDUSTRY | 12 | Dec 9, 2020 | clinicaltrials |
| NCT02947152 | HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma | terminated | Phase 1 | 9 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 8, 2020 | clinicaltrials |
| NCT03603379 | Doxorubicin-loaded Anti-EGFR-immunoliposomes (C225-ILs-dox) in High-grade Gliomas(GBM-LIPO) | completed | Phase 1 | 9 | University Hospital, Basel, SwitzerlandOTHER | 1 | Dec 8, 2020 | clinicaltrials |
| NCT01363232 | Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients | completed | Phase 1 | 89 | Array Biopharma, now a wholly owned subsidiary of PfizerINDUSTRY | 7 | Oct 5, 2020 | clinicaltrials |
| NCT01352273 | MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations | completed | Phase 1 | 69 | Array Biopharma, now a wholly owned subsidiary of PfizerINDUSTRY | 5 | Sep 30, 2020 | clinicaltrials |
| NCT00946647 | A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). | completed | Phase 1 / Phase 2 | 113 | Novartis PharmaceuticalsINDUSTRY | 14 | Aug 4, 2020 | clinicaltrials |
| NCT00112242 | Immunotherapy of Stage III/IV Melanoma Patients | completed | Phase 1 | 39 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Jun 18, 2020 | clinicaltrials |
| NCT01308294 | Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients(LAG-3/IMP321) | terminated | Phase 1 / Phase 2 | 16 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT03294889 | ONE-SHOT Trial - Ultra-hypofractionated Single-dose SBRT for Prostate Cancer | recruiting | Phase 1 / Phase 2 | 45 | University Hospital, GenevaOTHER | 1 | May 14, 2020 | clinicaltrials |
| NCT01831089 | Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors | completed | Phase 1 | 69 | PharmaMarINDUSTRY | 3 | Apr 10, 2020 | clinicaltrials |
| NCT03242993 | [18F]-AZAFOL AS POSITRON EMISSION TOMOGRAPHY (PET) TRACER in FR Positive Cancer Imaging | completed | Phase 1 | 15 | University of Lausanne HospitalsOTHER | 1 | Feb 28, 2020 | clinicaltrials |
| NCT02541604 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors | terminated | Phase 1 / Phase 2 | 87 | Hoffmann-La RocheINDUSTRY | 11 | Feb 25, 2020 | clinicaltrials |
| NCT02350673 | A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors | completed | Phase 1 | 70 | Hoffmann-La RocheINDUSTRY | 6 | Jan 18, 2020 | clinicaltrials |
| NCT02991911 | A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer(MEDI3726) | completed | Phase 1 | 33 | MedImmune LLCINDUSTRY | 3 | Jan 18, 2020 | clinicaltrials |
| NCT01962103 | Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 107 | CelgeneINDUSTRY | 7 | Dec 27, 2019 | clinicaltrials |
| NCT01954355 | LDE225 and Paclitaxel in Solid Tumors | completed | Phase 1 | 30 | Swiss Cancer InstituteOTHER | 1 | Dec 6, 2019 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials